| Autor: |
Michel Bazinet, Victor Pântea, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Mark Anderson, Jeff Gersch, Vera Holzmayer, Carina Elsner, Adalbert Krawczyk, Mary C. Kuhns, Gavin Cloherty, Ulf Dittmer, Andrew Vaillant |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Hepatology Communications, Vol 5, Iss 2, Pp 189-202 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2471-254X |
| DOI: |
10.1002/hep4.1633 |
| Popis: |
The nucleic acid polymer REP 2139 inhibits assembly/secretion of hepatitis B virus (HBV) subviral particles. Previously, REP 2139‐Ca and pegylated interferon (pegIFN) in HBV/hepatitis delta virus (HDV) coinfection achieved high rates of HDV RNA and hepatitis B surface antigen (HBsAg) loss/seroconversion in the REP 301 study (NCT02233075). The REP 301‐LTF study (NCT02876419) examined safety and efficacy during 3.5 years of follow‐up. In the current study, participants completing therapy in the REP 301 study were followed for 3.5 years. Primary outcomes were safety and tolerability, and secondary outcomes were HDV functional cure (HDV RNA target not detected [TND], normal alanine aminotransferase [ALT]), HBV virologic control (HBV DNA ≤2,000 IU/mL, normal ALT), HBV functional cure (HBV DNA TND; HBsAg |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text